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Objective: 
To assess the efficacy of out-patient intravaginal misoprostol versus in-patient intravaginal misoprostol for the 
treatment of first trimester incomplete miscarriage. 
 
Methods: 
A prospective randomised controlled trial was conducted at a tertiary medical center on 154 patients for the treatment 
of spontaneous first trimester incomplete miscarriage. The intervention group (n=77) received out-patient 
administration of misoprostol whereas the control group (n=77) received in-patient administration of misoprostol. 
The intravaginal misoprostol dosage administered was 800mcg 8 hourly to maximum of 3 doses. They were 
reassessed at Day 7. The primary outcome evaluated were success of evacuation, side effects, cost and patient 
acceptability. The secondary outcomes evaluated were mean reduction of endometrial thickness, days of passing out 
POC, duration of bleeding and mean reduction in hemoglobin. Assessment for treatment failure was done at day 7. 
Surgical evacuation was then offered. 
 
Results: 
Patient’s age, ethnic distribution, education level, parity and previous history of miscarriages were comparable 
between both the groups. The success rate was 89.2% and 85.7% for outpatient and inpatients respectively. Side 
effects observed include crampy abdominal pain, fever, nausea and diarrhoea were comparable requiring only 
symptomatic treatment. Duration of bleeding was 5.84 days in the outpatient as compared to 5.92 days in the 
inpatient group (p=0.420) whereas the mean haemoglobin difference of 0.40g/dl at diagnosis of incomplete 
miscarriage and Day 7 post treatment and was statistically significant (p=<0.001). The cost of treatment between the 
two groups was significant (outpatient-RM345 vs inpatient-RM 550). Patients were satisfied with both treatment 
methods and were keen in recommending the treatment methods to their friends. If a choice was given, patients 
would prefer outpatient intervention as compared to 21.2% inpatient and 10.6% repeat surgical evacuation as mode 
of treatment. 
 
Conclusion: 
Medical evacuation using intravaginal misoprostol 800mcg 8 hourly for a maximum of 3 doses in an outpatient 
setting has tolerable side effects, lesser cost and acceptable. It is as efficacious as inpatient administration in treating 
first trimester incomplete miscarriage. 
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